Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis

Rankin, Andrew L, Seth, Nilufer, Keegan, Sean, Andreyeva, Tatyana, Cook, Tim A, Edmonds, Jason, Mathialagan, Nagappan, Benson, Micah J +14 more·2013·The Journal of Immunology
DOI 10.4049/jimmunol.1301553

Cited by (125)

Items 101–125 of 125

  1. Lupus and Lupus Overlap Diseases: Emerging Therapies
    Vasileios C. Kyttaris · 2016 · Elsevier eBooks
  2. Management of Autoimmune and Inflammatory Disorders in the Setting of Infection or Immunodeficiency
    Winn W Chatham · 2018 · Springer eBooks
  3. New treatments of systemic lupus erythematosus
    Vasileios C. Kyttaris · 2020 · Elsevier eBooks
  4. Therapeutic Effects of Bruton’s Tyrosine Kinase Inhibitor HM71224 as Monotherapy and in Combination with Methotrexate on Collagen-Induced Arthritis in Rats
    InHwan Bae, Yu-Yon Kim, Sunyoung Jang, Joo‐Yun Byun, Taehun Song, Kyung-Jin Choi, Yongwei Piao, Kwee Hyun Suh, YoungGil Ahn, Young‐Hoon Kim et al. · 2020
  5. Faculty Opinions recommendation of Delineating the role of cooperativity in the design of potent PROTACs for BTK.
    Robert A. Copeland · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  6. Clinical advances in immunotherapy for immune-mediated glomerular diseases
    Bihui Tang, Xiao Yang · 2023 · Clinical and Experimental Medicine
  7. Synthesis of a Potent Bruton's Tyrosine Kinase Inhibitor Labelled With Carbon‐14 and Deuterium
    Bachir Latli, Magnus Eriksson · 2025 · Journal of Labelled Compounds and Radiopharmaceuticals
  8. Additional file 1 of Bruton’s tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder
    Ye Liu, Huang, Zhenning, Zhang, Tian-Xiang, Han, Bin, Guili Yang, Jia, Dongmei, Yang, Li, Liu, Qiang, Lau, Alexander Y. L., Paul, Friedemann et al. · 2024 · Figshare
  9. Traitement de l’hémophilie A à l’aide d’ARNm codant le facteur VIII et prévention de la réponse immunitaire dirigée contre le facteur VIII thérapeutique
    Jules Russick · 2018
  10. First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of BIIB091, an Oral BTK Inhibitor, in Healthy Adult Participants
    Hui‐Hsin Tsai, Yi Gu, Katherine A. Riester, Sherman Chu, Eris Bame, Million Arefayene, Jeanelle LYL Kam, Alex Coppell, Jerome Hanna, Brian T. Hopkins et al. · 2026 · Drug Design Development and Therapy
  11. Emerging pharmacotherapies for chronic spontaneous urticaria: spotlight on BTK inhibitors
    Özge Sevil Karstarlı Bakay, Emek Kocatürk · 2026 · Expert Opinion on Pharmacotherapy
  12. Molecular endotyping in systemic lupus erythematosus: an integrative framework toward precision therapy
    Yuya Terajima, Yoshinori Matsumoto, Shoichi Nawachi, Yosuke Asano, Keigo Hayashi, Yoshia Miyawaki, Haruki Watanabe, Eri Katsuyama, Takayuki Katsuyama, Jun Wada · 2026 · Frontiers in Immunology
  13. BindingDB Entry 50003078: Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.
    BindingDB · 2020 · UC San Diego
  14. BindingDB Entry 50000272: Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
    BindingDB · 2019 · UC San Diego
  15. BindingDB Entry 50001805: The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    BindingDB · 2020 · UC San Diego
  16. BindingDB Entry 50010916: Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity.
    BindingDB · 2021 · UC San Diego
  17. BindingDB Entry 50011454: Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK.
    BindingDB · 2022 · UC San Diego
  18. BindingDB Entry 50007980: Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
    BindingDB · 2021 · UC San Diego
  19. BindingDB Entry 50047871: Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locke
    BindingDB · 2018 · UC San Diego
  20. BindingDB Entry 50018849: Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases.
    BindingDB · 2024 · UC San Diego
  21. BindingDB Entry 50018682: 4-Aminopyrazolopyrimidine scaffold and its deformation in the design of tyrosine and serine/threonine kinase inhibitors in medicinal chemistry.
    BindingDB · 2024 · UC San Diego
  22. BindingDB Entry 50008690: Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning.
    BindingDB · 2021 · UC San Diego
  23. BindingDB Entry 50009939: Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177).
    BindingDB · 2021 · UC San Diego
  24. BindingDB Entry 50010667: Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
    BindingDB · 2021 · UC San Diego
  25. BindingDB Entry 50007369: Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
    BindingDB · 2021 · UC San Diego